Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-09 00:43 • The Motley Fool Positive Axe Cap view: Selective

The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.

Axe note: Pfizer offers a clearer path past patent losses and drug pricing challenges than Bristol Myers Squibb.

2026-10-08 23:22 • The Motley Fool Positive Axe Cap view: Selective

The article compares AMD and ASML as semiconductor investment options for 2026. AMD designs AI chips for data centers with strong 34.3% revenue growth, while ASML manufactures the lithography equipment essential for producing advanced chips. The author recommends ASML due to its monopolistic position serving the entire AI chip industry, despite AMD's impressive performance. ASML trades at more conservative valuations with a Forward P/E of 41.6x versus AMD's 84.5x.

Axe note: ASML's near-monopoly on chip-making equipment gives it an edge over AMD's fast-growing but competitive chip design business.

2026-10-08 23:07 • The Motley Fool Neutral Axe Cap view: Neutral

Intel stock has surged over 200% in 2026 after government and Nvidia investments, driven by progress in its chip foundry segment with 18A nanometer technology. However, 2027 will be a critical 'show me' year where Intel must attract major clients to justify its expensive valuation. The analyst projects the stock will likely remain flat around $110 per share, with downside risk to $85-89 if revenue growth disappoints below Wall Street's 15% expectation.

Axe note: Intel’s chip tech leap is exciting, but the stock needs real client wins to keep soaring.